Data di Pubblicazione:
2023
Abstract:
Cachexia is a debilitating wasting syndrome and highly prevalent comorbidity in cancer patients. It manifests especially with energy and mitochondrial metabolism aberrations that promote tissue wasting. We recently identified nicotinamide adenine dinucleotide (NAD+) loss to associate with muscle mitochondrial dysfunction in cancer hosts. In this study we confirm that depletion of NAD+ and downregulation of Nrk2, an NAD+ biosynthetic enzyme, are common features of severe cachexia in different mouse models. Testing NAD+ repletion therapy in cachectic mice reveals that NAD+ precursor, vitamin B3 niacin, efficiently corrects tissue NAD+ levels, improves mitochondrial metabolism and ameliorates cancer- and chemotherapy-induced cachexia. In a clinical setting, we show that muscle NRK2 is downregulated in cancer patients. The low expression of NRK2 correlates with metabolic abnormalities underscoring the significance of NAD+ in the pathophysiology of human cancer cachexia. Overall, our results propose NAD+ metabolism as a therapy target for cachectic cancer patients.
Tipologia CRIS:
03A-Articolo su Rivista
Elenco autori:
Beltrà, Marc; Pöllänen, Noora; Fornelli, Claudia; Tonttila, Kialiina; Hsu, Myriam Y; Zampieri, Sandra; Moletta, Lucia; Corrà, Samantha; Porporato, Paolo E; Kivelä, Riikka; Viscomi, Carlo; Sandri, Marco; Hulmi, Juha J; Sartori, Roberta; Pirinen, Eija; Penna, Fabio
Link alla scheda completa:
Link al Full Text:
Pubblicato in: